

## DAFTAR PUSTAKA

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. *J Am Coll Cardiol*. 2013;62(16):1495–539.
2. Maggioni AP. Review of the new ESC guidelines for the pharmacological management of chronic heart failure. *Eur Hear Journal, Suppl*. 2005;7(J):15–20.
3. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. *ESC Hear Fail*. 2014;1(1):4–25.
4. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: Treatment considerations for a dual epidemic. *Circulation*. 2009;119(18):2516–25.
5. Badan Penelitian dan Pengembangan Kesehatan Kementrian RI 2013. *Riset Kesehatan Dasar 2013*. 2013.
6. Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: A systematic review 2004-2016. *BMC Cardiovasc Disord*. 2018;18(1):1–11.
7. Inamdar A, Inamdar A. Heart Failure: Diagnosis, Management and Utilization. *J Clin Med*. 2016;5(7):62.
8. Ramani G V., Uber PA, Mehra MR. Chronic heart failure: Contemporary diagnosis and management. *Mayo Clin Proc*. 2010;85(2):180–95.
9. Bytyçi I, Bajraktari G. Mortality in heart failure patients. *Anadolu Kardiyol Derg*. 2015;15(1):63–8.
10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2016;37(27):2129-2200m.
11. Mesquita ET, Barbeta LMDS, Correia ET de O. Heart failure with mid-range ejection fraction – State of the art. *Arq Bras Cardiol*. 2019;112(6):784–90.
12. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail*. 2017;19(12):1574–85.

13. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K, et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. *Int J Cardiol.* 2018;271:132–9.
14. Lyu S, Yu L, Tan H, Liu S, Liu X, Guo X, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: Insights from a multi-centre registry study in China. *BMC Cardiovasc Disord.* 2019;19(1):1–12.
15. Choi BG, Rha SW, Yoon SG, Choi CU, Lee MW, Kim SW. Association of Major Adverse Cardiac Events up to 5 Years in Patients With Chest Pain Without Significant Coronary Artery Disease in the Korean Population. *J Am Heart Assoc.* 2019;8(12):6–8.
16. Kitakata H, Kohno T, Kohsaka S, Shiraishi Y, Parizo JT, Niimi N, et al. Prognostic Implications of Early and Midrange Readmissions After Acute Heart Failure Hospitalizations: A Report From a Japanese Multicenter Registry. *J Am Heart Assoc.* 2020;9(10):1–10.
17. Wang N, Hales S, Barin E, Tofler G. Characteristics and outcome for heart failure patients with mid-range ejection fraction. *J Cardiovasc Med.* 2018;19(6):297–303.
18. Lainscak M, Spoletini I, Coats A. Definition and Classification of Heart Failure. *Int Cardiovasc Forum J.* 2017;10:3–7.
19. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with t. *Circulation.* 2009;119(14):1977–2016.
20. O’connor. Clinical Classification of Heart Failure Patients Using Cardiac Function During Exercise. *Physiol Behav.* 2016;176(1):139–48.
21. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. *Circulation.* 2017;136(6):e137–61.
22. Branca L, Sbolli M, Metra M, Fudim M. Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European

Society of Cardiology guidelines. ESC Hear Fail. 2020;381–99.

23. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nat Rev Cardiol.* 2016;13(6):368–78.
24. Themistocleous I, Stefanakis M, Douda H. Coronary Heart Disease Part I: Pathophysiology and Risk Factors. *J Phys Act Nutr Rehabil.* 2017;168–75.
25. Oh GC, Cho H-J. Blood pressure and heart. *Clin Hypertens.* 2020;26(1):1–8.
26. Mathew T, Williams L, Navaratnam G, Rana B, Wheeler R, Collins K, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract.* 2017;4(2):G1–13.
27. Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. 2003;89:939–43.
28. Dianne SP, Andrea B, Aparna R, Andrew S, Jonathan C. Acute Rheumatic Fever and Rheumatic Heart Disease. 2017. 1–57 p.
29. Jackson G, R Gibbs C, K Davies M, YH Lip G. ABC of Heart Failure Pathophysiology. *Br Med J.* 2000;320:167–70.
30. Wright P, Thomas M. Pathophysiology and management of heart failure. *Clin Pharm.* 2018;10(12):1–21.
31. Segovia Cubero J, Alonso-Pulpón Rivera L, Pereira Moral R, Silva Melchor L. Heart Failure: Etiology and Approach to Diagnosis. *Rev Esp Cardiol.* 2004;57(3):250–9.
32. Azaraksh A, Ivanov G, Bulanova N, Stazhadze L, Nikolaeva M, Vostrikov V. Contemporary Approach To Diagnosis of Subclinical Heart Failure. *Georgian Med News.* 2017;10(264):66–72.
33. Benyounes N, Van Der Vynckt C, Tibi T, Iglesias A, Gout O, Lang S, et al. Left Ventricular End Diastolic Volume and Ejection Fraction Calculation: Correlation between Three Echocardiographic Methods. *Cardiol Res Pract.* 2020;2020:1–7.
34. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph. *J Am Soc Echocardiogr.* 2005;18(12):1440–63.

35. Sadeghpour A, Alizadehasl A. Chapter 5 - Echocardiography. Practical Cardiology. Elsevier Inc.; 2017. 67–111 p.
36. Chengode S. Left ventricular global systolic function assessment by echocardiography. *Ann Card Anaesth*. 2016;19(5):S26–34.
37. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJS, Cleland JGF, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. *Eur Heart J*. 2000;21(16):1387–96.
38. Lang RM, Badano LP, Victor MA, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39.e14.
39. Berliner D, Bauersachs J. Current drug therapy in chronic heart failure - The new guidelines of the European Society of Cardiology (ESC). *Korean Circ J*. 2017;47(5):543–54.
40. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. *Korean J Intern Med*. 2019;34(1):11–43.
41. Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R. Heart failure: A class review of pharmacotherapy. *P T*. 2017;42(7):464–72.
42. Marcy TR, Ripley TL. Aldosterone antagonists in the treatment of heart failure. *Am J Heal Pharm*. 2006;63(1):49–58.
43. Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The Problem With Composite End Points in Cardiovascular Studies. The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2008;51(7):701–7.
44. Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Sacco RL, et al. Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data from the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial. *Stroke*. 2016;47(8):2031–7.
45. Solomon SD, Anavekar N, Skali H, McMurray JJV, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. *Circulation*. 2005;112(24):3738–44.
46. Luscher TF. Mechanisms and outcomes of heart failure: From HFpEF, HFmrEF, and HFrfEF to transplantation. *Eur Heart J*. 2018;39(20):1749–53.
47. Vergaro G, Ghionzoli N, Innocenti L, Taddei C, Giannoni A, Valleggi A, et al.

Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. *J Am Heart Assoc.* 2019;8(20):1–11.

48. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American heart association/American stroke association. *Stroke.* 2013;44(7):2064–89.
49. Gheorghide M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: Problems and perspectives. *J Am Coll Cardiol.* 2013;61(4):391–403.
50. Dahlan MS. *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan.* 4th ed. Jakarta: Epidemiologi Indonesia; 2016. 13 p.
51. Kaya A, Bayramoğlu A, Bektaş O, Yaman M, Günaydın ZY, Topcu S, et al. The prognostic value of altitude in patients with heart failure with reduced ejection fraction. *Anatol J Cardiol.* 2019;22(6):300–8.
52. Marwick TH. Ejection Fraction Pros and Cons: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2018;72(19):2360–79.
53. Akintunde A, Akinwusi O, Opadijo G. Left ventricular hypertrophy, geometric patterns and clinical correlates among treated hypertensive Nigerians. *Pan Afr Med J.* 2010;4:1–8.
54. Tschöpe C, Pieske B. Heart failure with mid-range EF (HFmrEF): A mildly reduced EF does not imply a mild disease. *Hear Metab.* 2017;(74):8–12.
55. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study. *Eur J Heart Fail.* 2017;19(10):1258–69.
56. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. *Eur Heart J.* 2010;31(19):2369–429.
57. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. *Eur Heart J.* 2018;39(20):1770–80.
58. Lam CSP, Anand I, Zhang S, Shimizu W, Narasimhan C, Park SW, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. *Eur J Heart Fail.* 2013;15(8):928–36.

59. Harding E, Marques SC, Mes M, Murphy M. Spotlight on HFpEF: heart failure with preserved ejection fraction. *Hear Fail Policy Netw* [Internet]. 2020.
60. Rinaldi L, Herlambang KS, Novitasari A. Karakteristik Hasil Pemeriksaan Ekokardiografi pada Penderita Gagal Jantung yang Dirawat di Rumah Sakit Roemani Periode 1 Januari – 31 Desember 2010 *Characteristic of Echocardiography Results in Patient with Heart Failure treated in Roemani Hospital Perio*. 2010;1(2):60–9.
61. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. *J Am Coll Cardiol*. 2017;70(20):2476–86.
62. Rajadurai J, Tse HF, Wang CH, Yang NI, Zhou J, Sim D. Understanding the Epidemiology of Heart Failure to Improve Management Practices: An Asia-Pacific Perspective. *J Card Fail*. 2017;23(4):327–39.
63. Farré N, Lupon J, Roig E, Gonzalez-costello J, Vila J, Perez S, et al. Clinical characteristics , one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction : a multicentre prospective observational study in Catalonia ( Spain ). 2017;1–9.
64. Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan. *ESC Hear Fail*. 2019;6(3):475–86.
65. Gheisari F, Emami M, Raeisi Shahraki H, Samipour S, Nematollahi P. The Role of Gender in the Importance of Risk Factors for Coronary Artery Disease. *Cardiol Res Pract*. 2020;2020:1–6.
66. Spence JD, Pilote L. Importance of sex and gender in atherosclerosis and cardiovascular disease. *Atherosclerosis*. 2015;241(1):208–10.
67. Severino P, D'Amato A, Pucci M, Infusino F, Birtolo LI, Mariani MV, et al. Ischemic heart disease and heart failure: Role of coronary ion channels. *Int J Mol Sci*. 2020;21(9).
68. Albakri A. Ischemic heart failure: A review of clinical status and meta-analysis of diagnosis and clinical management methods. *Clin Med Investig*. 2018;3(4):1–15.
69. Elgendy IY, Mahtta D, Pepine CJ. Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. *Circ Res*. 2019;124(11):1520–35.
70. Sophie L, Bruce J. Diastolic Dysfunction as a Link Between Hypertension and Heart Failure. *Drugs Today (Barc)*. 2008;44(7):503–13.
71. Ozlek B, Ozlek E, Ağuş HZ, Tekinalp M, Kahraman S, Cil C, et al. Patients

with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study. *Eur J Intern Med.* 2019;61(48):88–95.

72. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart.* 2007;93(9):1137–46.
73. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J, et al. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. *Int J Cardiol.* 2017;240:265–70.
74. Aronow WS. Current treatment of heart failure with reduction of left ventricular ejection fraction. *Expert Rev Clin Pharmacol.* 2016;9(12):1619–31.
75. Tadic M, Cuspidi C, Plein S, Belyavskiy E, Heinzl F, Galderisi M. Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies. *J Clin Med.* 2019;8(6):792.
76. Al MF, Sultan GM, Dawood AAE, Sebaeia NF, Moustafa MLH. Assessment of left atrial function in patients with heart failure: correlation with brain natriuretic peptide levels. *Menoufia Med J.* 2020;33:835–42.
77. Kjaergaard J, Iversen KK, Akkan D, Moller JE, Kober L V, Torp-pedersen C, et al. Predictors of right ventricular function as measured by tricuspid annular plane systolic excursion in heart failure. 2009;7(Lv):1–7.
78. Mostafa S. Assessment of right ventricular systolic function in heart failure with preserved, reduced and mid-range ejection fraction. *Indian Heart J.* 2019;71(5):406–11.
79. Zhou Y, Liu L, Cheng T, Wang DX, Yang HY, Zhang BW, et al. Grade 3 Echocardiographic Diastolic Dysfunction Is Associated with Increased Risk of Major Adverse Cardiovascular Events after Surgery: A Retrospective Cohort Study. *Anesth Analg.* 2019;129(3):651–8.
80. Lindley KJ, Williams D, Conner SN, Verma A, Cahill AG, Davila-Roman VG. The Spectrum of Pregnancy-Associated Heart Failure Phenotypes: An Echocardiographic Study. *Int J Cardiovasc Imaging.* 2020;36(9):1637–45.
81. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. *J Am Med Assoc.* 2006;296(18):2209–16.
82. Federmann M, Hess OM. Differentiation between systolic and diastolic dysfunction. *Eur Heart J.* 2016;15(3):2–6.
83. Klara M, Roland G, Adam R, Tamas R, Robert H, Kalman T. From hypertension to heart failure. *World J Hypertens.* 2015;5(AJ2):85–92.

84. Erlanda W, Rasyid H El, Syafri M, Nindrea RD. Padang Skoring Elektrokardiografi untuk Memprediksi Fraksi Ejeksi Ventrikel Kiri pada Gagal Jantung Kronik. *Indones J Cardiol*. 2019;39(4):156–65.
85. Yap J, Tay WT, Teng THK, Anand I, Richards AM, Ling LH, et al. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. *J Am Heart Assoc*. 2019;8(17):e013114.
86. Ostadal B, Dhalla NS. Cardiac adaptations: Molecular mechanisms. *Card Adapt Mol Mech*. 2013;4:1–465.
87. Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population level—risk factors, screening, and outcomes. *Nat Rev Cardiol*. 2011;8(12):673–85.
88. Al-Jarallah M, Rajan R, Al-Zakwani I, Dashti R, Bulbanat B, Ridha M, et al. Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the middle east. *Oman Med J*. 2020;35(1).
89. Mesquita ET, Jorge AJL, Rabelo LM, Souza Jr. CV. Understanding Hospitalization in Patients with Heart Failure. *Int J Cardiovasc Sci*. 2016;30(1):81–90.

